PepGen (PEPG) Competitors $4.50 -0.05 (-1.10%) Closing price 04:00 PM EasternExtended Trading$4.51 +0.01 (+0.31%) As of 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PEPG vs. CMPS, SVRA, MGTX, GLUE, SNDL, ZVRA, SIGA, RGNX, CMPX, and MLTXShould you be buying PepGen stock or one of its competitors? The main competitors of PepGen include COMPASS Pathways (CMPS), Savara (SVRA), MeiraGTx (MGTX), Monte Rosa Therapeutics (GLUE), SNDL (SNDL), Zevra Therapeutics (ZVRA), Siga Technologies (SIGA), REGENXBIO (RGNX), Compass Therapeutics (CMPX), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry. PepGen vs. Its Competitors COMPASS Pathways Savara MeiraGTx Monte Rosa Therapeutics SNDL Zevra Therapeutics Siga Technologies REGENXBIO Compass Therapeutics MoonLake Immunotherapeutics PepGen (NASDAQ:PEPG) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation. Do analysts prefer PEPG or CMPS? PepGen presently has a consensus target price of $8.40, indicating a potential upside of 86.67%. COMPASS Pathways has a consensus target price of $16.00, indicating a potential upside of 156.41%. Given COMPASS Pathways' stronger consensus rating and higher possible upside, analysts clearly believe COMPASS Pathways is more favorable than PepGen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PepGen 2 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33COMPASS Pathways 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do insiders and institutionals believe in PEPG or CMPS? 58.0% of PepGen shares are held by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are held by institutional investors. 5.2% of PepGen shares are held by company insiders. Comparatively, 3.9% of COMPASS Pathways shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is PEPG or CMPS more profitable? COMPASS Pathways' return on equity of -87.89% beat PepGen's return on equity.Company Net Margins Return on Equity Return on Assets PepGenN/A -92.51% -70.39% COMPASS Pathways N/A -87.89%-57.77% Which has more volatility and risk, PEPG or CMPS? PepGen has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.21, meaning that its stock price is 121% more volatile than the S&P 500. Does the media favor PEPG or CMPS? In the previous week, COMPASS Pathways had 1 more articles in the media than PepGen. MarketBeat recorded 3 mentions for COMPASS Pathways and 2 mentions for PepGen. PepGen's average media sentiment score of 0.76 beat COMPASS Pathways' score of 0.24 indicating that PepGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PepGen 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive COMPASS Pathways 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation & earnings, PEPG or CMPS? COMPASS Pathways is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPepGenN/AN/A-$89.98M-$2.96-1.52COMPASS PathwaysN/AN/A-$155.12M-$1.84-3.39 SummaryCOMPASS Pathways beats PepGen on 8 of the 13 factors compared between the two stocks. Get PepGen News Delivered to You Automatically Sign up to receive the latest news and ratings for PEPG and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PEPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PEPG vs. The Competition Export to ExcelMetricPepGenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$147.60M$3.42B$6.17B$10.67BDividend YieldN/A2.24%5.72%4.86%P/E Ratio-1.5223.2129.5928.52Price / SalesN/A477.49578.90129.07Price / CashN/A45.5937.1261.42Price / Book1.2410.3412.046.52Net Income-$89.98M-$52.53M$3.32B$276.75M7 Day Performance-6.25%-0.29%-0.17%0.21%1 Month Performance130.77%10.83%5.75%1.68%1 Year Performance-48.28%14.10%65.69%32.79% PepGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PEPGPepGen3.195 of 5 stars$4.50-1.1%$8.40+86.7%-47.7%$147.60MN/A-1.5230CMPSCOMPASS Pathways2.7705 of 5 stars$6.75+3.5%$16.00+137.0%-0.5%$625.54MN/A-3.67120Upcoming EarningsSVRASavara3.1003 of 5 stars$4.11+13.9%$7.50+82.5%+18.8%$623.94MN/A-8.2220Trending NewsAnalyst ForecastGap UpHigh Trading VolumeMGTXMeiraGTx4.3495 of 5 stars$8.24+6.3%$24.00+191.3%+46.2%$623.47M$33.28M-4.04300News CoverageAnalyst ForecastInsider TradeGLUEMonte Rosa Therapeutics2.2563 of 5 stars$9.87-1.8%$15.33+55.4%+76.1%$620.68M$177.99M27.4290News CoverageSNDLSNDL3.0645 of 5 stars$2.36+1.3%$4.50+90.7%+2.3%$612.27M$671.81M-8.742,516ZVRAZevra Therapeutics2.693 of 5 stars$11.15+3.1%$24.00+115.2%+29.0%$606.54M$23.61M-53.1020Analyst DowngradeSIGASiga Technologies2.0057 of 5 stars$8.48+2.2%N/A+24.2%$594.33M$138.72M7.5040RGNXREGENXBIO4.3757 of 5 stars$12.64+7.8%$28.38+124.5%+27.1%$592.53M$83.33M-3.67370CMPXCompass Therapeutics2.2774 of 5 stars$4.05-4.9%$13.10+223.5%+127.3%$589.08M$850K-9.0020MLTXMoonLake Immunotherapeutics2.8976 of 5 stars$9.35+2.5%$36.00+285.0%-80.0%$585.78MN/A-3.362Trending News Related Companies and Tools Related Companies COMPASS Pathways Alternatives Savara Alternatives MeiraGTx Alternatives Monte Rosa Therapeutics Alternatives SNDL Alternatives Zevra Therapeutics Alternatives Siga Technologies Alternatives REGENXBIO Alternatives Compass Therapeutics Alternatives MoonLake Immunotherapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PEPG) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PepGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PepGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PEPG Stock Alerts